These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 9297270)
1. [The efficacy of Sulodexide--a low-molecular heparin--in the therapy of diabetic nephropathy]. Shestakova MV; Chugunova LA; Vorontsov AV; Dedov II Ter Arkh; 1997; 69(6):34-7. PubMed ID: 9297270 [TBL] [Abstract][Full Text] [Related]
2. [A trial of the use of the low-molecular heparin sulodexide in the therapy of diabetic nephropathy]. Zalevskaia AG; Astamirova KhS; Karpova IA; Popova SG Ter Arkh; 1998; 70(3):71-4. PubMed ID: 9575594 [TBL] [Abstract][Full Text] [Related]
3. [Sulodexide in the treatment of diabetic nephropathy]. Rasovskiĭ BL; Tarasov AV; Trel'skaia NIu; Severina TI; Chernykh EF Klin Med (Mosk); 1998; 76(7):40-2. PubMed ID: 9742778 [TBL] [Abstract][Full Text] [Related]
4. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Lambers Heerspink HJ; Fowler MJ; Volgi J; Reutens AT; Klein I; Herskovits TA; Packham DK; Fraser IR; Schwartz SL; Abaterusso C; Lewis J; Diabet Med; 2007 Nov; 24(11):1290-5. PubMed ID: 17956455 [TBL] [Abstract][Full Text] [Related]
5. One year course of oral sulodexide in the management of diabetic nephropathy. Achour A; Kacem M; Dibej K; Skhiri H; Bouraoui S; El May M J Nephrol; 2005; 18(5):568-74. PubMed ID: 16299683 [TBL] [Abstract][Full Text] [Related]
6. Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Tamsma JT; van der Woude FJ; Lemkes HH Nephrol Dial Transplant; 1996 Jan; 11(1):182-5. PubMed ID: 8649631 [TBL] [Abstract][Full Text] [Related]
7. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Sulikowska B; Olejniczak H; Muszyńska M; Odrowaz-Sypniewska G; Gaddi A; Savini C; Cicero AF; Laghi L; Manitius J Am J Nephrol; 2006; 26(6):621-8. PubMed ID: 17191008 [TBL] [Abstract][Full Text] [Related]
8. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Heerspink HL; Greene T; Lewis JB; Raz I; Rohde RD; Hunsicker LG; Schwartz SL; Aronoff S; Katz MA; Eisner GM; Mersey JH; Wiegmann TB; Nephrol Dial Transplant; 2008 Jun; 23(6):1946-54. PubMed ID: 18089623 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. Blouza S; Dakhli S; Abid H; Aissaoui M; Ardhaoui I; Ben Abdallah N; Ben Brahim S; Ben Ghorbel I; Ben Salem N; Beji S; Chamakhi S; Derbel A; Derouiche F; Djait F; Doghri T; Fourti Y; Gharbi F; Jellouli K; Jellazi N; Kamoun K; Khedher A; Letaief A; Limam R; Mekaouer A; Miledi R; Nagati K; Naouar M; Sellem S; Tarzi H; Turki S; Zidi B; Achour A; J Nephrol; 2010; 23(4):415-24. PubMed ID: 20175052 [TBL] [Abstract][Full Text] [Related]
10. [Sulodexid and nephrotic syndrome in patients with diabetic nephropathy]. Valociková I Vnitr Lek; 2011 May; 57(5):507-10. PubMed ID: 21695933 [TBL] [Abstract][Full Text] [Related]
11. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Lewis EJ; Lewis JB; Greene T; Hunsicker LG; Berl T; Pohl MA; de Zeeuw D; Heerspink HL; Rohde RD; Atkins RC; Reutens AT; Packham DK; Raz I; Am J Kidney Dis; 2011 Nov; 58(5):729-36. PubMed ID: 21872376 [TBL] [Abstract][Full Text] [Related]
12. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. Katavetin P; Eiam-Ong S; Suwanwalaikorn S J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002 [TBL] [Abstract][Full Text] [Related]
13. [The effectiveness of ramipril in the treatment of diabetic nephropathy in normotensive children and adolescents]. Sivous GI; Kasatkina EP; Samsonova LN; Voĭchik EA; Gerasimov NP Klin Med (Mosk); 1997; 75(12):52-4. PubMed ID: 9503815 [TBL] [Abstract][Full Text] [Related]
14. Albuminuria: a target for treatment of type 2 diabetic nephropathy. de Zeeuw D Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686 [TBL] [Abstract][Full Text] [Related]
15. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. Remuzzi G; Macia M; Ruggenenti P J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S90-7. PubMed ID: 16565256 [TBL] [Abstract][Full Text] [Related]
17. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients. Steinke JM; Mauer M; Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710 [TBL] [Abstract][Full Text] [Related]
18. [Microalbuminuria in diabetes: setting the points for treatment]. Lehnert H; Klose S; Lobmann R; Zehnder D MMW Fortschr Med; 2006 May; 148(21):28-30, 33; quiz 34. PubMed ID: 16796185 [TBL] [Abstract][Full Text] [Related]
19. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Skrha J; Perusicová J; Pont'uch P; Oksa A Diabetes Res Clin Pract; 1997 Oct; 38(1):25-31. PubMed ID: 9347243 [TBL] [Abstract][Full Text] [Related]
20. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Ficociello LH; Perkins BA; Silva KH; Finkelstein DM; Ignatowska-Switalska H; Gaciong Z; Cupples LA; Aschengrau A; Warram JH; Krolewski AS Clin J Am Soc Nephrol; 2007 May; 2(3):461-9. PubMed ID: 17699452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]